Bringing
innovation to life.

Dedicated Leadership

Our leadership is made up of senior pharma executives united in the mission of bringing life-saving treatments to patients.

Clearing Chaos

We are dedicated to applying insights from basic science in psychiatry and immunology to bring new solutions to save lives.

Innovative Therapies

We leverage 30 years of basic science in psychiatry and immunology to identify and develop treatments for orphan diseases.

Rapid Solutions

We excel at innovative novel therapeutic development for rapid deployment.

Chief Executive Officer

Jonathan C. Javitt,
M.D., M.P.H.

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.

Team

Mr. Besthof is a global biopharmaceutical executive with a 25+year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases areas, including small as well as billion dollar brands in Ophthalmology, Neuroscience, Pain, Pulmonary Vascular Disease, etc. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Bank and for various consulting firms. He holds a B.A. from Case Western Reserve University and a Masters in Int’l Management from the Thunderbird School of Global Management.

Brian has over 30 years of multinational scientific and legal experience in FDA-regulated pharmaceuticals and biologics, with an emphasis on both branded and generic FDA-regulated products, intellectual property, regulatory affairs, strategic business development, mergers and acquisitions, corporate governance and corporate transactions including licensing.  He also has substantial experience in biotech/pharma R&D innovation and management, and has had key responsibilities in large merger integration efforts.  Prior to joining NeuroRx, Brian was VP/Chief Legal & Regulatory Officer for Stuart Therapeutics, Sr. VP/Chief Legal Officer & Corporate Secretary for The Sun Products Corporation, and was a partner at Sterne, Kessler, Goldstein & Fox, PLLC. Before entering into his legal practice, Brian spent nearly 10 years in academic and corporate biopharma R&D, most recently with Becton Dickinson & Co.  Brian holds a J.D., cum laude, from Georgetown University Law Center, an M.S. and a Ph.D. in Microbiology/Biochemistry from The Pennsylvania State University, and was a postdoctoral fellow in Biochemistry and Hematology/Oncology at Boston University School of Medicine.

Dr. Lavin is a highly-respected biostatistician with more than 30 years of experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics in 1983, a company now known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 FDA approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years where he has advised FDA on complex statistical and policy issues.

James H. Brandon, CPA, has practiced as a Maryland licensed Certified Public Accountant for over 35 years. Mr. Brandon has been a partner in several firms, sold a practice to American Express, was the managing member of a Caribbean island resort, and is currently a sole practitioner serving the Washington DC. Metropolitan area. His clients span the country and he currently has business and individual clients in over 25 states.

Mr. Brandon’s area of concentration is business and individual accounting and taxation. Mr. Brandon is well versed in accounting systems and has conducted seminars in the use of certain software. Mr. Brandon was the auditor of several local governments in Maryland. Mr. Brandon also prepares probate court accounting for personal representatives. Mr. Brandon is also a court-appointed bankruptcy CPA.

Mr. Brandon is a member of

  • The American Institute of CPAs
    The Maryland Association of CPAs
    The Association of Practicing CPAs
    The Maryland Society of Accounting and Tax Professionals

Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. He began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally-prominent laboratories and headquarters organizations, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute.  Upon retiring as a highly decorated senior officer (O-6), he assumed the leadership of the Potomac Institute for Policy Studies, which he continues to serve as President Emeritus.  Following his ten year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career there as Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral).

Dennis has served as adviser to Cabinet Secretaries, congressional committees, and to major corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (Flight Surgeon School), the University of Southern California, the London School of Economics, and Harvard Business School, with award of the Ph.D. in experimental psychology, four master’s degrees, and additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption.  He has published widely, was elected by faculty in 1999 to full professor, and has served at multiple universities, full- and part-time in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine.  For the past 12 years, Dr. McBride has served as adjunct Professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.

Mr. Pines previously served as Associate Commissioner of the US Food and Drug Administration.

Dr. Morganroth received both his undergraduate degree and medical degree from the University of Michigan in Ann Arbor. He completing both his internship and residency in Internal Medicine at Yale University School of Medicine. He completed a Pulmonary and Critical Care Fellowship at the University of Colorado Health Sciences Center in Denver. He was an Assistant Professor at the University of Michigan in the Pulmonary and Critical Care Division from 1984-1990. At the University of Michigan, in addition to being active in patient care, he was also director of the Critical Care Medicine Unit, co-director of the critical care fellowship training program and carried out basic research on acute lung injury. Since 1990 he has been the director of the research department in the Pulmonary, Critical Care and Sleep Division of The Oregon Clinic. He is active in patient care, teaching and clinical research. He has been the principal investigator in many research studies and authored multiple journal articles and book chapters on topics related to respiratory disease.

Dr. Harry Peled is the Medical director of Cardiology and Critical Care at Saint Jude medical center in Fullerton, California.  In addition to being board-certified in cardiology and critical care he is also board-certified in geriatrics, palliative care and Neurocritical care.  He graduated from Albert Einstein College of Medicine with special distinction for research. He has  authored work published In the New England Journal of Medicine, Chest, Annals of internal medicine, and many others. He also  holds a masters in bio ethics and health policy from Loyola University.

Board of Directors

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.

Mr. Chaim Hurvitz has been the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd from April 2002 to 2010 was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University, which was awarded in 1985.

Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuro-psychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.

Mr. Flynn is a founding investor in NeuroRx. He is an entrepreneur with more than 30 years of senior executive experience. He has provided leadership to numerous successful organizations and has served in a variety of roles, including CEO, COO, CFO and advisor.  Pat currently serves as COO of Good Measures, Inc.  He co-founded Predilytics, Inc., which was sold to Welltock, Inc.  Previously, Pat served as COO and then as CEO of Health Dialog, which was sold to BUPA International. Pat continued with BUPA, opening their business in the GCC and China.  Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management.

Dr. Glied, whose principal areas of research are in health policy reform and mental health care policy, was named Dean of New York University’s Robert F. Wagner Graduate School of Public Service in 2013.  From 1989-2013, Dr. Glied was professor of health policy and management at Columbia University’s Mailman School of Public Health and served as chair of the department of health policy and management from 1998-2009.  In 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She had previously served as senior economist for health care and labor market policy on the President’s Council of Economic Advisers in 1992-1993, under Presidents Bush and Clinton, and participated in the Clinton Health Care Task Force.

Mr. Gorovitz is a partner of the AHG Group. In addition to his 25 years of legal experience in complex commercial transactions, he has considerable involvement in early stage biotechnology and health information technology companies.

Mr. Troy has been General Counsel at GlaxoSmithKline plc since September 2, 2008 and has been its Senior Vice President since September 2008. Mr. Troy is responsible for leading GSK’s legal department in protecting GSK’s intellectual property; managing litigation; supporting Business Development transactions; and Business Compliance and Risk management. He has been Secretary of Human Genome Sciences Inc. since August 2012. Prior to joining GSK, Mr. Troy served as a Member of the Life Sciences Practice and Appellate Litigation Group and a Partner at Sidley Austin LLP. In 2001, he was appointed by President Bush to serve as Chief Counsel for the US Food and Drug Administration, where he was a primary liaison to the White House and the US Department of Health and Human Services. From 2006 to 2007, he chaired the American Bar Association’s Section of Administrative Law and was previously adjunct scholar at the American Enterprise Institute in Washington, DC.

Get information about the expanded access program